Press Releases + News Year: - Any -202620252024202320222021202020192018201720162015201420132012201120102009 Items per page 102550 Date Title and Summary View Toggle SummaryJan 07, 2015 Final Phase 1 Trial Results Demonstrate Galectin Therapeutics' GR-MD-02 is Safe With Potential for Therapeutic Effect on Fibrosis in NASH Patients With Advanced Fibrosis View HTML Final Phase 1 Trial Results Demonstrate Galectin Therapeutics' GR-MD-02 is Safe With Potential for Therapeutic Effect on Fibrosis in NASH Patients With Advanced Fibrosis 31.8 KB Toggle SummaryDec 01, 2014 Galectin Therapeutics to Present at 7th Annual LD Micro Main Event Conference View HTML Galectin Therapeutics to Present at 7th Annual LD Micro Main Event Conference 18.2 KB Toggle SummaryNov 10, 2014 Galectin Therapeutics Reports Third Quarter 2014 Financial Results and Provides Update on Company's Development Program View HTML Galectin Therapeutics Reports Third Quarter 2014 Financial Results and Provides Update on Company's Development Program 30.8 KB Toggle SummaryNov 09, 2014 Galectin Therapeutics' Phase 1 Data Presented at AASLD Annual Meeting Advances GR-MD-02 Into Phase 2 Clinical Development View HTML Galectin Therapeutics' Phase 1 Data Presented at AASLD Annual Meeting Advances GR-MD-02 Into Phase 2 Clinical Development 27 KB Toggle SummaryOct 01, 2014 Galectin Therapeutics' Abstract Accepted as Oral Presentation at The Liver Meeting(R), Annual Meeting of the American Association for the Study of Liver Diseases Presentation of Ongoing Phase 1 GR-MD-02 Data to be Held Sunday, November 9, 3:30pm EST View HTML Galectin Therapeutics' Abstract Accepted as Oral Presentation at The Liver Meeting(R), Annual Meeting of the American Association for the Study of Liver Diseases 23 KB Toggle SummarySep 24, 2014 Galectin Therapeutics Elects Gilbert S. Omenn, M.D., Ph.D., a Leading Cancer Researcher, to Its Board of Directors View HTML Galectin Therapeutics Elects Gilbert S. Omenn, M.D., Ph.D., a Leading Cancer Researcher, to Its Board of Directors 26.1 KB Toggle SummarySep 15, 2014 Galectin Therapeutics Announces Issuance of U.S. Patent for GR-MD-02 in Diabetic Nephropathy View HTML Galectin Therapeutics Announces Issuance of U.S. Patent for GR-MD-02 in Diabetic Nephropathy 16.3 KB Toggle SummarySep 10, 2014 Galectin Therapeutics to Present at Aegis Capital Corporation 2014 Healthcare and Technology Conference View HTML Galectin Therapeutics to Present at Aegis Capital Corporation 2014 Healthcare and Technology Conference 17.2 KB Toggle SummaryAug 07, 2014 Galectin Therapeutics Reports Second Quarter 2014 Financial Results View HTML Galectin Therapeutics Reports Second Quarter 2014 Financial Results 28.9 KB Toggle SummaryAug 05, 2014 Galectin Therapeutics Receives U.S. Patent for GR-MD-02 Composition of Matter Patent Covers Use of Company's Galectin Inhibitor in NASH, Fibrotic Diseases, Cancer and Other Disorders in Which Galectins are Involved in Pathogenesis View HTML Galectin Therapeutics Receives U.S. Patent for GR-MD-02 Composition of Matter 18.8 KB Pagination First page First Previous page Previous … Page 24 Current page 25 Page 26 Page 27 … Next page Next Last page Last
Final Phase 1 Trial Results Demonstrate Galectin Therapeutics' GR-MD-02 is Safe With Potential for Therapeutic Effect on Fibrosis in NASH Patients With Advanced Fibrosis 31.8 KB
Galectin Therapeutics Reports Third Quarter 2014 Financial Results and Provides Update on Company's Development Program 30.8 KB
Galectin Therapeutics' Phase 1 Data Presented at AASLD Annual Meeting Advances GR-MD-02 Into Phase 2 Clinical Development 27 KB
Galectin Therapeutics' Abstract Accepted as Oral Presentation at The Liver Meeting(R), Annual Meeting of the American Association for the Study of Liver Diseases 23 KB
Galectin Therapeutics Elects Gilbert S. Omenn, M.D., Ph.D., a Leading Cancer Researcher, to Its Board of Directors 26.1 KB
Galectin Therapeutics to Present at Aegis Capital Corporation 2014 Healthcare and Technology Conference 17.2 KB
